Table 3.
Multivariate Analysis of Baseline Factors Associated With Sustained Visual Acuity Loss
| Factor | Patients at Risk, No.a | Sustained Visual Acuity Loss, No. (%) | Adjusted Odds Ratio (95% CI) | P Value |
|---|---|---|---|---|
| Baseline nonfoveal geographic atrophy | ||||
| None or questionable | 959 | 51 (5.3) | 1 [Reference] | .006 |
| Present | 70 | 10 (14.3) | 2.86 (1.35–6.08) | |
| Baseline area of CNV (disc area) | ||||
| ≤1 | 417 | 14 (3.4) | 1 [Reference] | .007 |
| >1-≤2 | 203 | 10 (4.9) | 1.63 (0.70–3.76) | |
| >2-≤4 | 190 | 14 (7.4) | 2.44 (1.13–5.28) | |
| >4 | 100 | 11 (11.0) | 3.91 (1.70–9.03) | |
| Unknown | 119 | 12 (10.1) | 3.30 (1.47–7.44) | |
| Drug group | ||||
| Ranibizumab | 528 | 24 (4.6) | 1 [Reference] | .03 |
| Bevacizumab | 501 | 37 (7.4) | 1.83 (1.07–3.14) | |
| Regimen group | ||||
| Monthly always | 262 | 11 (4.2) | 1 [Reference] | .24 |
| Monthly in year 1, as needed in year 2 | 252 | 20 (7.9) | 1.92 (0.89–4.15) | |
| As needed always | 515 | 30 (5.8) | 1.37 (0.67–2.81) | |
Abbreviation: CNV, choroidal neovascularization.
a
One patient was excluded for an unknown status on baseline nonfoveal geographic atrophy.